You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

second line therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Intrahepatic Cholangiocarcinoma Trial in Tianjin (Regorafenib and HAIC, FOLFOX)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Sep 7, 2022

HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • trastuzumab, bevacizumab with paclitaxel (triple combination)
  • (no location specified)
Dec 6, 2022

Liver Cancer Trial in Houston (Bevacizumab, Erlotinib)

Completed
Has Results
  • Liver Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Nov 3, 2022

Cholangiocarcinoma Trial in Düsseldorf (Combination of Lonsurf® and Irinotecan)

Recruiting
  • Cholangiocarcinoma
  • Combination of Lonsurf® and Irinotecan
  • Düsseldorf, NRW, Germany
    Klinik für Gastroenterologie, Hepatologie und Infektiologie
Dec 22, 2022

Stomach Tumors Trial in Wuhan (Fruquintinib, Sintilimab)

Not yet recruiting
  • Stomach Neoplasms
  • Wuhan, Hubei, China
    Wuhan Union Hospital, China
Nov 22, 2022

Lower-risk Myelodysplastic Syndrome Trial in Tampa (JSP191)

Recruiting
  • Lower-risk Myelodysplastic Syndrome
  • Tampa, Florida
    Moffitt Cancer Center
Jun 20, 2023

NSCLC Trial in Zhengzhou (L-TIL, Tislelizumab, Docetaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • L-TIL, Tislelizumab, Docetaxel
  • Zhengzhou, Henan, China
    No.127 Dongming Road
May 17, 2023

Bile Duct Adenocarcinoma Trial in Hangzhou (surufatinib plus cadonilimab)

Recruiting
  • Bile Duct Adenocarcinoma
  • surufatinib plus cadonilimab
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 15, 2023

Neuroendocrine Tumor Trial in Beijing (PM8002, FOLFIRI)

Recruiting
  • Neuroendocrine Neoplasm
  • Beijing, China
    Chinese PLA General Hospital
May 25, 2023

Esophageal Squamous Cell Carcinoma Trial (Decitabine plus Penpulimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Decitabine plus Penpulimab
  • (no location specified)
Feb 23, 2022

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

Oncology, Neuroendocrine Carcinoma Trial in United Kingdom (Liposomal Irinotecan, Fluorouracil, Folinic Acid)

Active, not recruiting
  • Oncology
  • Neuroendocrine Carcinoma
  • Liposomal Irinotecan
  • +3 more
  • Glasgow, United Kingdom
  • +3 more
Dec 2, 2022

Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial (RP3,

Not yet recruiting
  • Locally Advanced Hepatocellular Carcinoma
  • +2 more
  • RP3
  • +2 more
  • (no location specified)
Feb 8, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)

Recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • Experimental drug
  • Control Rx
  • Hefei, Anhui, China
  • +11 more
Mar 13, 2023

Adenocarcinoma of the Stomach Trial in Goyang (Anti-EGFR antibody in combination with weekly paclitaxel)

Recruiting
  • Adenocarcinoma of the Stomach
  • Anti-EGFR antibody in combination with weekly paclitaxel
  • Goyang, Gyeonggi, Korea, Republic of
    National Cancer Center
Nov 29, 2022

Immune Markers in Pediatric ITP

Not yet recruiting
  • ITP - Immune Thrombocytopenia
  • complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
  • (no location specified)
Oct 17, 2023

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma

Not yet recruiting
  • Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
  • Surufatinib + envafolimab
  • (no location specified)
Feb 1, 2023

Hepatocellular Carcinoma Trial in Winston-Salem (TheraBionic, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Oct 26, 2022

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 15, 2022

Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma Trial in Tianjin (PD-1 inhibitor)

Recruiting
  • Hodgkin Lymphoma, Adult
  • +2 more
  • PD-1 inhibitor
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Dec 14, 2021

NSCLC Metastatic Trial (bevacizumab plus nab-paclitaxel and platinum)

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
  • bevacizumab plus nab-paclitaxel and platinum
  • (no location specified)
Jun 2, 2022

Leukemia, Myeloid, Chronic-Phase Trial in Germany (Ponatinib)

Active, not recruiting
  • Leukemia, Myeloid, Chronic-Phase
  • Halle (Saale), Saxony-Anhalt, Germany
  • +9 more
Sep 9, 2022

Overall Survival Trial in Qingdao (Anlotinib, PD-1 inhibitor)

Recruiting
  • Overall Survival
  • Anlotinib, PD-1 inhibitor
  • Qingdao, Shandong, China
  • +1 more
Feb 23, 2022

Colorectal Tumors Trial in Shenzhen (Apatinib Mesylate Tablets, Bevacizumab Injection)

Recruiting
  • Colorectal Neoplasms
  • Apatinib Mesylate Tablets
  • Bevacizumab Injection
  • Shenzhen, Guang Dong, China
    Shenzhen People's Hospital
Sep 26, 2021